Emre Yekedüz1,2, Deniz Tural3, İsmail Ertürk4, Serdar Karakaya5, Cihan Erol6, Özlem Ercelep7, Çağatay Arslan8, Özlem Nuray Sever9, Saadettin Kılıçkap10,11, Nihan Şentürk Öztaş12, Ahmet Küçükarda13, Orçun Can14, Berna Öksüzoğlu5, Mehmet Ali Şendur6, Nuri Karadurmuş4, Yüksel Ürün15,16. 1. Faculty of Medicine Department of Medical Oncology, Ankara University, Cebeci, 06590, Ankara, Turkey. 2. Ankara University Cancer Research Institute, Ankara, Turkey. 3. Department of Medical Oncology, University of Health Sciences, Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey. 4. Department of Medical Oncology, University of Health Sciences, Gülhane Education and Research Hospital, Ankara, Turkey. 5. Medical Oncology Department, University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey. 6. Faculty of Medicine, Department of Medical Oncology, Ankara Yıldırım Beyazıt University, Ankara, Turkey. 7. Faculty of Medicine, Department of Medical Oncology, Marmara University, Istanbul, Turkey. 8. Faculty of Medicine, Department of Medical Oncology, İzmir University of Economics, İzmir, Turkey. 9. Faculty of Medicine, Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey. 10. Faculty of Medicine, Department of Medical Oncology, Hacettepe University, Ankara, Turkey. 11. Faculty of Medicine, Department of Medical Oncology, İstinye University, Istanbul, Turkey. 12. Cerrahpaşa Faculty of Medicine, Division of Medical Oncology, İstanbul University-Cerrahpaşa, Istanbul, Turkey. 13. Faculty of Medicine, Department of Medical Oncology, Trakya University, Edirne, Turkey. 14. Department of Medical Oncology, University of Health Sciences, Prof. Dr. Cemil Taşçıoğlu City Hospital, Istanbul, Turkey. 15. Faculty of Medicine Department of Medical Oncology, Ankara University, Cebeci, 06590, Ankara, Turkey. yukselurun@gmail.com. 16. Ankara University Cancer Research Institute, Ankara, Turkey. yukselurun@gmail.com.
Abstract
BACKGROUND: Pan-immune-inflammation value (PIV) is an easily accessible immune marker based on peripheral blood to estimate prognosis in patients with cancer. This study evaluates the prognostic value of PIV in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab. METHODS: In this retrospective cohort study, patients with mRCC treated with nivolumab in the second line and beyond were selected from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) database. PIV was calculated using the following formula: neutrophil (103/mm3) x monocyte (103/mm3) x platelet (103/mm3)/lymphocyte (103/mm3). RESULTS: A total of 152 patients with mRCC were included in this study. According to cut-off value for PIV, 77 (50.7%) and 75 (49.3%) patients fell into PIV-low ([Formula: see text] 372) and PIV-high (> 372) groups, respectively. In multivariate analysis, PIV-high (HR: 1.64, 95% CI 1.04-2.58, p = 0.033 for overall survival (OS); HR: 1.55, 95% CI 1.02-2.38, p = 0.042 for progression-free survival (PFS)) was independent risk factor for OS and PFS after adjusting for confounding variables, such as performance score, the International mRCC Database Consortium (IMDC) risk score, and liver metastasis. CONCLUSION: This study established that pre-treatment PIV might be a prognostic biomarker in patients with mRCC treated with nivolumab in the second line and beyond.
BACKGROUND: Pan-immune-inflammation value (PIV) is an easily accessible immune marker based on peripheral blood to estimate prognosis in patients with cancer. This study evaluates the prognostic value of PIV in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab. METHODS: In this retrospective cohort study, patients with mRCC treated with nivolumab in the second line and beyond were selected from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) database. PIV was calculated using the following formula: neutrophil (103/mm3) x monocyte (103/mm3) x platelet (103/mm3)/lymphocyte (103/mm3). RESULTS: A total of 152 patients with mRCC were included in this study. According to cut-off value for PIV, 77 (50.7%) and 75 (49.3%) patients fell into PIV-low ([Formula: see text] 372) and PIV-high (> 372) groups, respectively. In multivariate analysis, PIV-high (HR: 1.64, 95% CI 1.04-2.58, p = 0.033 for overall survival (OS); HR: 1.55, 95% CI 1.02-2.38, p = 0.042 for progression-free survival (PFS)) was independent risk factor for OS and PFS after adjusting for confounding variables, such as performance score, the International mRCC Database Consortium (IMDC) risk score, and liver metastasis. CONCLUSION: This study established that pre-treatment PIV might be a prognostic biomarker in patients with mRCC treated with nivolumab in the second line and beyond.
Authors: Ugo De Giorgi; Giuseppe Procopio; Diana Giannarelli; Roberto Sabbatini; Alessandra Bearz; Sebastiano Buti; Umberto Basso; Manfred Mitterer; Cinzia Ortega; Paolo Bidoli; Francesco Ferraù; Lucio Crinò; Antonio Frassoldati; Paolo Marchetti; Enrico Mini; Alessandro Scoppola; Claudio Verusio; Giuseppe Fornarini; Giacomo Cartenì; Claudia Caserta; Cora N Sternberg Journal: Clin Cancer Res Date: 2019-04-09 Impact factor: 12.531
Authors: Mehmet Asim Bilen; Giselle Marie Almeida Dutcher; Yuan Liu; Deepak Ravindranathan; Haydn T Kissick; Bradley C Carthon; Omer Kucuk; Wayne B Harris; Viraj A Master Journal: Clin Genitourin Cancer Date: 2018-01-04 Impact factor: 2.872
Authors: Francesca Corti; Sara Lonardi; Rossana Intini; Massimiliano Salati; Elisabetta Fenocchio; Carmen Belli; Beatrice Borelli; Marta Brambilla; Alessandra A Prete; Virginia Quarà; Maria Antista; Matteo Fassan; Federica Morano; Andrea Spallanzani; Margherita Ambrosini; Giuseppe Curigliano; Filippo de Braud; Vittorina Zagonel; Giovanni Fucà; Filippo Pietrantonio Journal: Eur J Cancer Date: 2021-04-23 Impact factor: 9.162
Authors: Thilo Gambichler; Kai Horny; Thomas Mentzel; Ingo Stricker; Andrea Tannapfel; Christina H Scheel; Bertold Behle; Daniel R Quast; Yi-Pei Lee; Markus Stücker; Laura Susok; Jürgen C Becker Journal: J Cancer Res Clin Oncol Date: 2022-05-03 Impact factor: 4.553
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Toni K Choueiri; Thomas Powles; Mauricio Burotto; Bernard Escudier; Maria T Bourlon; Bogdan Zurawski; Victor M Oyervides Juárez; James J Hsieh; Umberto Basso; Amishi Y Shah; Cristina Suárez; Alketa Hamzaj; Jeffrey C Goh; Carlos Barrios; Martin Richardet; Camillo Porta; Rubén Kowalyszyn; Juan P Feregrino; Jakub Żołnierek; David Pook; Elizabeth R Kessler; Yoshihiko Tomita; Ryuichi Mizuno; Jens Bedke; Joshua Zhang; Matthew A Maurer; Burcin Simsek; Flavia Ejzykowicz; Gisela M Schwab; Andrea B Apolo; Robert J Motzer Journal: N Engl J Med Date: 2021-03-04 Impact factor: 91.245